Informations

Liquid biopsy is not a new concept in the field of breast cancer, but its clinical applications continue to evolve, requiring fresh insights into the technologies, terminology, biomarkers, and future directions. On Tuesday, December 10 (Central Time), during the “Educational Session 2: Liquid Biopsy: MRD, ctDNA, and Monitoring Response to Treatment” at the 2024 San…

Pathogenic germline mutations in certain genes are known to increase the risk of hereditary breast cancer. Approximately 5% to 10% of all breast cancer cases are hereditary, primarily driven by such mutations, with BRCA1/2 being the most common. Germline mutations also guide treatment decisions, as patients with pathogenic BRCA1/2 germline mutations may benefit from PARP…

On September 19, 2024, a randomized, double-blind, parallel-controlled, multicenter phase III clinical study, co-led by Professor Shukui Qin from the Nanjing Tianyinshan Hospital Affiliated to China Pharmaceutical University and Professor Liwei Wang from the Renji Hospital, Shanghai Jiaotong University School of Medicine, was published in Signal Transduction and Targeted Therapy (IF = 40.8), a prestigious…

From December 10–13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious gatherings in breast cancer research, SABCS showcased cutting-edge developments from the past year, including research breakthroughs, clinical practice insights, treatment advances, and technological innovations. Among these, studies led or…

Treatment strategies for HR+/HER2+ breast cancer have long been a focus of research. On December 11 (Central Time), during the 47th San Antonio Breast Cancer Symposium (SABCS), the results of the TOUCH study (Abstract RF1-02) were released, drawing significant attention. This international, open-label Phase II trial explored the efficacy of a chemotherapy-free approach in the…

Global breast cancer researchers are tackling cutting-edge questions to inform clinical trial design and guide future treatment decisions. At the 2024 San Antonio Breast Cancer Symposium (SABCS), an internationally renowned panel of experts explored two of the most pressing topics in translational medicine—how to define triple-negative breast cancer (TNBC) and the development of tumor-agnostic therapies.

The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcases the latest research findings, clinical practices, treatment advancements, and technological innovations in breast cancer from the past year.